Scientists may have found a way around the limitations of engineered T cells by borrowing a few tricks from cancer itself. By studying mutations in malignant T cells that cause lymphoma, they zeroed in on one that imparted exceptional potency to engineered T cells.
Scientists may have found a way around the limitations of engineered T cells by borrowing a few tricks from cancer itself. By studying mutations in malignant T cells that cause lymphoma, they zeroed in on one that imparted exceptional potency to engineered T cells.
Inserting a gene encoding this unique mutation into normal human T cells made them more than 100 times more potent at killing cancer cells without any signs of becoming toxic. While current immunotherapies work only against cancers of the blood and bone marrow, the engineered T cells were able to kill tumors derived from skin, lung and stomach in mice. The team has already begun working toward testing this new approach in people. Scientists at the UC San Francisco and Northwestern Medicine may have found a way around the limitations of engineered T cells by borrowing a few tricks from cancer itself. By studying mutations in malignant T cells that cause lymphoma, they zeroed in on one that imparted exceptional potency to engineered T cells. Inserting a gene encoding this unique mutation into normal human T cells made them more than 100 times more potent at killing cancer cells without any signs of becoming toxic. While current immunotherapies work only against cancers of the blood and bone marrow, the T cells engineered by Northwestern and UCSF were able to kill tumors derived from skin, lung and stomach in mice. The team has already begun working toward testing this new approach in people. "We used nature's roadmap to make better T cell therapies," said Dr. Jaehyuk Choi, an associate professor of dermatology and of biochemistry and molecular genetics at Northwestern University Feinberg School of Medicine."The superpower that makes cancer cells so strong can be transferred into T cell therapies to make them powerful enough to eliminate what were once incurable cancers." "Mutations underlying the resilience and adaptability of cancer cells can super-charge T cells to survive and thrive in the harsh conditions that tumors create," said Kole Roybal, associate professor of microbiology and immunology at UCSF, center director for the Parker Institute for Cancer Immunotherapy Center at UCSF, and a member of the Gladstone Institute of Genomic Immunology.Creating effective immunotherapies has proven difficult against most cancers because the tumor creates an environment focused on sustaining itself, redirecting resources like oxygen and nutrients for its own benefit. Often, tumors hijack the body's immune system, causing it to defend the cancer, instead of attacking it. Not only does this impair the ability of regular T cells to target cancer cells, it undermines the effectiveness of the engineered T cells that are used in immunotherapies, which quickly tire against the tumor's defenses. "For cell-based treatments to work under these conditions," Roybal said,"we need to give healthy T cells abilities that are beyond what they can naturally achieve." The Northwestern and UCSF teams screened 71 mutations found in patients with T cell lymphoma and identified which ones could enhance engineered T cell therapies in mouse tumor models. Eventually, they isolated one that proved both potent and non-toxic, subjecting it to a rigorous set of safety tests. "Our discoveries empower T cells to kill multiple cancer types," said Choi, a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University."This approach performs better than anything we've seen before." Their discoveries can be incorporated into treatments for many types of cancer, the scientists said. "T cells have the potential to offer cures to people who are heavily pretreated and have a poor prognosis," Choi said."Cell therapies are living drugs, because they live and grow inside the patient and can provide long-term immunity against cancer." In collaboration with the Parker Institute for Cancer Immunotherapy and Venrock, Roybal and Choi are building a new company, Moonlight Bio, to realize the potential of their groundbreaking approach. They are currently developing a cancer therapy that they hope to begin testing in people within the next few years. "We see this as the starting point," Roybal said."There's so much to learn from nature about how we can enhance these cells and tailor them to different types of diseases." The research was supported by the Parker Institute for Cancer Immunotherapy, NIH grants , Cancer Moonshot grant U54 CA244438, the Mark Foundation for Cancer Research, the Bakewell Foundation, and UCSF Helen Diller Family Comprehensive Cancer Center. Roybal and Choi are inventors on patents related to these discoveries and are co-founders and equity holders in Moonlight Bio.Julie Garcia, Jay Daniels, Yujin Lee, Iowis Zhu, Kathleen Cheng, Qing Liu, Daniel Goodman, Cassandra Burnett, Calvin Law, Chloë Thienpont, Josef Alavi, Camillia Azimi, Garrett Montgomery, Kole T. Roybal, Jaehyuk Choi.In a promising form of immunotherapy known as CAR T-cell therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of ... Immunotherapies called chimeric antigen receptor T cells use genetically engineered versions of a patient's own immune cells to fight cancer. These treatments have energized cancer care, ... Researchers are developing ready-to-use, off-the-shelf therapeutic T cells. These are genetically engineered T cells that are manufactured from normal, healthy donors. The cells are expanded and well ... CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient's own T-cells by adding a piece of an antibody that recognizes unique ...
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Using Generative AI as a Lie Detector and the FTC's Concerns on Mental Health ChatbotsThis article discusses the use of generative AI as a lie detector and the potential concerns of the FTC regarding mental health chatbots that promise miracle cures. It highlights the impact of computational power on various aspects of society and the evolution of computing models.
Read more »
Scientists Solve Long-Standing Block Copolymer Research ConundrumResearchers at Pohang University of Science and Technology (POSTECH) have solved a long-standing block copolymer research problem through polymer chain end modifications. The study has achieved tangible manifestations of intricate polymer structures that were previously only theoretical, garnering substantial academic attention. The findings have been published in a journal article, sparking considerable interest within academic circles.
Read more »
Empress Of: Using Songs as Manifestation Tools for Something BetterEmpress Of, the alt pop artist, is using songs as manifestation tools for something better, moving past heartache and embracing a lighter side of her personality.
Read more »
Using Silicon to Control Artificial IntelligenceResearchers are exploring ways to encode rules governing the training and deployment of advanced algorithms directly into computer chips to limit the potential harm caused by AI systems.
Read more »
Alabama Executes Inmate Using Nitrogen GasAlabama becomes the first U.S. state to execute a person using nitrogen gas, killing 58-year-old Kenneth Smith after the Supreme Court rejects his appeal. Smith was convicted for a murder-for-hire killing in 1988.
Read more »
Billions Facing Clean Water Crisis By 2050, Scientists Warn — Here’s WhyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »